Fortschritte der Medizin · 1994
[Dimethylsulfoxide (DMSO) gel in treatment of acute tendopathies. A multicenter, placebo-controlled, randomized study].
Клиническое исследованиеАннотация на английскомСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kneer W, Kühnau S, Bias P, Haag R F
Аннотация
METHOD: In a placebo-controlled double-blind study, 157 patients with acute tenopathies (periarthropathia humeroscapularis or lateral epicondylitis) were randomized to treatment with either DMSO gel 10% applied three times a day (n = 77) or the gel excipient (n = 80). The treatment phase was 14 days long and included four examinations. Treatment was started within 72 hours after the onset of the acute symptoms.
RESULTS: Pain of movement under loading and the mobility of the joints were significantly improved after, respectively, 3 and 7 days treatment with DMSO, as compared with placebo. After 14 days on DMSO, a further improvement was observed, and 44% of the patients were pain-free (placebo 9%). In both groups, the substance was well or very well tolerated by more than 90% of the patients. No relevant changes in laboratory results or severe undesired events occurred under treatment. Undesired events were seen in 8 patients receiving DMSO treatment, and in 3 patients in the placebo group.
CONCLUSION: The results of this study confirm that Rheumabene (10% DMSO gel) is suitable for topical use in the treatment of acute tenopathy, producing clinically relevant results with little risk to the patient.
RESULTS: Pain of movement under loading and the mobility of the joints were significantly improved after, respectively, 3 and 7 days treatment with DMSO, as compared with placebo. After 14 days on DMSO, a further improvement was observed, and 44% of the patients were pain-free (placebo 9%). In both groups, the substance was well or very well tolerated by more than 90% of the patients. No relevant changes in laboratory results or severe undesired events occurred under treatment. Undesired events were seen in 8 patients receiving DMSO treatment, and in 3 patients in the placebo group.
CONCLUSION: The results of this study confirm that Rheumabene (10% DMSO gel) is suitable for topical use in the treatment of acute tenopathy, producing clinically relevant results with little risk to the patient.